1
|
Smal MA, Baldo BA. Inhibition of platelet-activating factor (PAF)-induced platelet aggregation by fatty acids from human saliva. Platelets 2021; 33:562-569. [PMID: 34348059 DOI: 10.1080/09537104.2021.1961705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Experiments were undertaken to identify the nature of a previously identified inhibitor of PAF-induced platelet aggregation (PA) in human saliva. Human saliva fractionated by preparative thin layer chromatography (TLC) yielded a fraction that co-migrated with fatty acids (FAs) and inhibited PAF-induced aggregation of platelets. Synthetic FAs tested for their capacities to inhibit 0.1 nM PAF-induced PA showed that only the cis-unsaturated compounds were inhibitory with activities of some of the polyunsaturated FAs (PUFA) reaching almost 100% at 20 μM. Eicosapentanoic acid (EPA) and 8,11,14-eicosatrienoic acid also deaggregated the PAF-induced aggregates. With the exception of oleic acid (OLA), cis-monounsaturated FAs, and elaidic acid, the trans isomer of OLA, were poor inhibitors. In a direct comparison with other platelet agonists, ADP, thrombin, and ionophore A23187, the active saliva fraction and selected individual (FA) inhibited, to greater or lesser extent, PA induced by each of the agonists. EPA, OLA, linoleic acid (LNA), and the active saliva fraction were potent inhibitors of ADP-induced PA, EPA completely inhibited thrombin-induced PA and the saliva fraction showed only weak - moderate inhibitory activity to both thrombin- and ionophore A23187-induced PA. Other reports of endogenous PAF inhibitors in mammalian tissues are compared to the present results. PAF can trigger and amplify inflammatory cascades suggesting a possible modulation role for cis-unsaturated FAs in some diseases.
Collapse
Affiliation(s)
- Mary A Smal
- Kolling Institute of Medical Research, Royal North Shore Hospital of Sydney, St Leonards
| | - Brian A Baldo
- Kolling Institute of Medical Research, Royal North Shore Hospital of Sydney, St Leonards.,Department of Medicine, University of Sydney, NSW, Australia
| |
Collapse
|
2
|
Avramopoulou V, Antonopoulou S, Argyropoulos D, Froussios C, Demopoulos CA. Synthesis of a new phosphoglycolipid with biological activity towards platelets. Int J Biochem Cell Biol 1997; 29:767-74. [PMID: 9251244 DOI: 10.1016/s1357-2725(97)00020-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Various synthetic as well as naturally occurring compounds have been found to exhibit platelet-activating factor (PAF)-like activity or to act as specific PAF inhibitors. In this work we have synthesized a new phosphoglycolipid, methyl 2,3,4-tri-O-acetyl-6-(1'-O-stearoyl-2'-O- acetyl-DL-glycero-3'-phosphoryl)-alpha-D-glucopyranoside ammonium salt, using a combination of known synthetic steps. This phosphoglycolipid was first purified on TLC (Rf 0.7, using chloroform/methanol/water, 65:25:4, v/v/v as solvent system). It was further purified onto a high performance liquid chromatography silica column with an elution system that contained acetonitrile and methanol (retention time 13.5 min). Its identification was based on chemical determinations and electrospray mass spectrometry analysis. The above compound induced washed platelet aggregation with an EC50 value at 2 x 10(-4) M. The aggregation curve was biphasic, the first wave of which was through the PAF way while the second one was through the ADP way. Treatment with acetylhydrolase resulted in a rapid decrease of the first wave of aggregation and in a slow decrease of the second wave. In lower concentrations, the phosphoglycolipid inhibited PAF- and thrombin-induced aggregation with IC50 values of the order of 10(-7) M. In conclusion, this phosphoglycolipid has a diverse biological activity. The PAF-like activity of this new lipid enforces the conception that PAF is a member of a large family consisting of lipid mediators.
Collapse
|
3
|
Trapali M, Mavri-Vavayanni M, Siafaka-Kapadai A. PAF-acetylhydrolase activity and PAF levels in pancreas and plasma of well-fed, diabetic and fasted rat. Life Sci 1996; 59:849-57. [PMID: 8761318 DOI: 10.1016/0024-3205(96)00375-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
PAF-AH activity was determined in pancreas homogenates. The enzyme activity was moderately stable upon storage at -20 degrees C. PAF and lyso-PAF were identified in rat pancreas and their concentrations were determined. PAF levels and PAF-AH activity were compared in the pancreatic tissue and plasma of three different groups of animals: well-fed, STZ-induced diabetic and fasted rats. The concentration of PAF in the pancreas of fasted rats was ten fold lower as compared with that of the well-fed or the diabetic animals. The last two groups had similar pancreatic PAF concentration. PAF levels in the plasma of fasted rats were seven fold lower than those of well-fed or diabetic rats, which were found to be similar. The enzyme PAF-AH had the highest activity in the pancreas of well-fed rats. On the contrary, the enzyme seems to be more active in the plasma of fasted as compared with diabetic and well-fed animals.
Collapse
Affiliation(s)
- M Trapali
- Department of Chemistry (Biochemistry), University of Athens, Greece
| | | | | |
Collapse
|
4
|
Aravindakshan TV, Sharma A. Effect of platelet activating factor on the motility and acrosome reaction of buffalo () spermatozoa. Theriogenology 1996; 45:991-9. [PMID: 16727858 DOI: 10.1016/0093-691x(96)00027-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/1994] [Accepted: 08/14/1995] [Indexed: 10/16/2022]
Abstract
Platelet activating factor (PAF; 1-0-alkyl-2 acetyl-sn-glycerol-3 phosphocholine) has been shown to have a wide range of biological activities. In this study, PAF was used to induce acrosome reactions in fresh as well as frozen-thawed buffalo spermatozoa at different incubation periods and PAF levels. As the period of incubation increased, there was a gradual decrease in motility and increase in acrosome reaction in both fresh and frozen-thawed spermatozoa. With increasing PAF levels, the motility of fresh spermatozoa decreased and acrosome reaction increased whereas in frozen-thawed semen, motility remained almost constant, and the increase in acrosome reaction was not pronounced. Differences in motility and acrosome reaction among different bulls, types of semen, periods of incubation and PAF levels were significant (P < 0.01). A PAF level of 100 microM and an incubation period of 15 min were found to be optimum for inducing acrosome reaction in buffalo spermatozoa, since at this combination acrosome reaction increased significantly (P < 0.01) over that of the control without much loss of motility.
Collapse
Affiliation(s)
- T V Aravindakshan
- Biotechnology Laboratory, National Dairy Research Institute, Karnal-132 001, India
| | | |
Collapse
|
5
|
Ammit AJ, O'Neill C. PAF released by preimplantation embryos binds to albumin. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 1996; 416:263-7. [PMID: 9131159 DOI: 10.1007/978-1-4899-0179-8_43] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- A J Ammit
- Human Reproduction Unit, Royal North Shore Hospital of Sydney, St. Leonards, NSW, Australia
| | | |
Collapse
|
6
|
Calligerou M, Siafaka-Kapadai A, Galanopoulou D, Weintraub ST, Mavri-Vavayanni M. Platelet activating factor and lyso-phosphatidylcholines from strawberry. PHYTOCHEMISTRY 1996; 41:89-92. [PMID: 8588879 DOI: 10.1016/0031-9422(95)00605-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
Lipids from strawberry fruits, leaves, achenes and pollen were separated into classes by TLC, purified by HPLC and tested for biological activity. A lipid fraction from fruits with the same chromatographic behaviour as authentic platelet activating factor (PAF) showed identical biological activity, namely, dose-dependent aggregation of washed rabbit platelets, inhibition of aggregation by CV 3988, platelet desensitization to PAF and vice versa, and loss of activity by alkaline hydrolysis and recovery of activity by reacetylation. The presence of PAF was confirmed by FAB mass spectrometry. Lyso-phosphatidylcholines, including lyso-PAF, were also found in all the plant parts tested.
Collapse
Affiliation(s)
- M Calligerou
- Department of Chemistry (Biochemistry), University of Athens, Zografou, Greece
| | | | | | | | | |
Collapse
|
7
|
Antonopoulou S, Demopoulos CA, Iatrou C. Blood cardiolipin in haemodialysis patients. Its implication in the biological action of platelet-activating factor. Int J Biochem Cell Biol 1996; 28:43-51. [PMID: 8624843 DOI: 10.1016/1357-2725(95)00116-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Bovine heart cardiolipin specifically inhibits platelet aggregation induced by PAF in vitro. In the past we have reported that patients with primary glomerulonephritis have increased PAF levels in plasma (Iatrou et al., 1995b). In this work we investigate the existence of cardiolipin in the blood of end-stage renal patients due to primary glomerulonephritis and we study its implication in the biological study of PAF. Lipids from blood samples of end-stage renal patients were extracted, fractionated onto silicic acid column and onto High Performance Liquid Chromatography (HPLC) cation exchange column. PAF fraction was removed and phospholipids were separated from the rest lipid fraction with current counter distribution and furthermore fractionated onto HPLC silica column. The results show: 1. cardiolipin is present in the blood of end-stage renal patients. 2. Blood cardiolipin specifically inhibits PAF-induced aggregation in washed rabbit platelets. 3. Scatchard plot analysis of PAF binding, in the presence of unlabelled PAF and in the presence of cardiolipin, shows that rabbit platelets possess two different types of binding sites. One of which is saturable and of high affinity, kD = 0.103 +/- 0.03 nM (SEM, n = 3) with 337 +/- 94 binding sites per platelet for PAF and kD = 0.087 +/- 0.02 nM with 371 +/- 92.7 binding sites per platelet for cardiolipin while the other one has almost infinite binding capacity. 4. Blood cardiolipin competes [3H]PAF binding in rabbit platelets. This work shows that cardiolipin exists in the blood of end-stage renal patients and specifically inhibits PAF-induced aggregation as well as PAF binding in rabbit platelets. The possible implication of the biological actions of cardiolipin in the anticardiolipin-antiphospholipid syndrome is also discussed.
Collapse
|
8
|
Davis TM, Binh TQ, van Phuong N, Sturm M, St John A, Dyer JR, Anh TK. The metabolism of platelet-activating factor in severe and cerebral malaria. J Infect 1995; 31:181-8. [PMID: 8586836 DOI: 10.1016/s0163-4453(95)80024-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
In order to examine the effects of platelet-activating factor (PAF) in complicated Plasmodium falciparum infections, plasma concentrations of lyso-PAF, stable metabolite and principal precursor of PAF, were measured in 25 Vietnamese adults with severe malaria. The concentration of PAF in the cerebrospinal fluid (CSF) was determined in a sub-group of 23 comatose patients and, together with that of lyso-PAF, in the plasma of 20 patients on recovery of consciousness. The concentration of lyso-PAF in the plasma was depressed on admission to hospital (median [range]; 21 [8-143] vs. 293 [215-410] ng/ml in 10 controls; P < 0.001). There was, however, no change in plasma activity of acetylhydrolase which converts PAF to lyso-PAF (P > 0.01 vs. controls) while simultaneous reduction in the concentration of lipoproteins associated with lyso-PAF were less than those of lyso-PAF per se in the plasma. The plasma concentration of lyso-PAF on admission was associated with parasitaemia and the concentration of serum triglycerides (rs = -0.42, P = 0.04 in each case), the latter being consistent with hepatic effects of PAF reported in previous studies. CSF concentrations of PAF on admission were low (2.3 [0.5-7.7] vs. 0.9 [0-2.5] ng/ml after recovery, P < 0.01) compared with values reported previously in bacterial meningitis. Plasma concentrations of lyso-PAF after recovery lay between admission and control values. While increased availability of PAF may reflect parasite burden and may modulate liver-mediated metabolic disturbances such as hypoglycaemia and lactic acidosis, the role of PAF in cerebral malaria is uncertain.
Collapse
Affiliation(s)
- T M Davis
- University of Western Australia, Department of Medicine, Fremantle Hospital
| | | | | | | | | | | | | |
Collapse
|
9
|
Woodard DS, Ostrom KK, McManus LM. Lipid inhibitors of platelet-activating factor (PAF) in normal human plasma. JOURNAL OF LIPID MEDIATORS AND CELL SIGNALLING 1995; 12:11-28. [PMID: 7551686 DOI: 10.1016/0929-7855(95)00004-a] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Endogenous, human plasma-derived lipids that inhibit the platelet stimulating activity of platelet-activating factor (PAF) have been identified. Chromatographic fractionation of neutral lipid PAF inhibitors revealed a majority of PAF inhibitory activity comigrating with cholesterol and a second peak localized with free fatty acids. Plasma phospholipids demonstrated three distinct PAF inhibitory fractions in TLC regions corresponding to those of sphingomyelin, phosphatidylcholine and phosphatidylethanolamine. Three fractions (one neutral lipid and two phospholipid) specifically inhibited PAF-induced platelet activation. Thus, there are both specific and non-specific lipid inhibitors of PAF in normal human plasma. These plasma lipids may be important in the specific regulation of the diverse, potent biological activities of PAF in various physiological states.
Collapse
Affiliation(s)
- D S Woodard
- Department of Pathology, University of Texas Health Science Center, San Antonio 78284-7750, USA
| | | | | |
Collapse
|
10
|
Nakayama R, Kumagai H, Saito K. Evidence for production of platelet-activating factor by yeast Saccharomyces cerevisiae cells. BIOCHIMICA ET BIOPHYSICA ACTA 1994; 1199:137-42. [PMID: 8123662 DOI: 10.1016/0304-4165(94)90108-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Various yeast strains were screened for platelet-activating factor (PAF) production. High PAF production was found mainly in the strains of Saccharomyces genus. Yeast PAF showed a typical platelet aggregation pattern, which was inhibited by specific PAF antagonists, such as CV-3988, CV-6209 and L-652731. The main molecular species of yeast PAF were identified as 1-palmitoleoyl-, -palmitoyl-, -oleoyl- and -stearoyl-2-acetyl-sn-glycero-3-phosphocholines (16:1, 16:0, 18:1 and 18:0 acylPAFs) and 1-hexadecenyl- and hexadecyl-2-acetyl-sn-glycero-3-phosphocholines (16:1 and 16:0 PAFs), by mass spectrometry. PAF formation in yeast cells increased at the middle stationary phase of growth.
Collapse
Affiliation(s)
- R Nakayama
- Department of Food Science, Kyoto Women's University, Japan
| | | | | |
Collapse
|
11
|
O'Flaherty JT, Tessner T, Greene D, Redman JR, Wykle RL. Comparison of 1-O-alkyl-, 1-O-alk-1'-enyl-, and 1-O-acyl-2-acetyl-sn-glycero-3-phosphoethanolamines and -3-phosphocholines as agonists of the platelet-activating factor family. BIOCHIMICA ET BIOPHYSICA ACTA 1994; 1210:209-16. [PMID: 8280772 DOI: 10.1016/0005-2760(94)90123-6] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Four naturally occurring platelet-activating factor (PAF) analogs, 1-alk-1'-enyl-2-acetyl-sn-glycero-3-phosphocholine, 1-hexadecanoyl-2-acetyl-sn-glycero-3-phosphocholine, 1-octadecanoyl-2-acetyl-sn-glycero-3-phosphocholine, and 1-alkyl-2-acetyl-sn-glycero-3-phosphoethanolamine, stimulated human neutrophils (PMN) to mobilize Ca2+, degranulate, and produce superoxide anion. They were, respectively, 5-, 300-, 500-, and 4000-fold weaker than PAF in each assay; inhibited PMN-binding of [3H]PAF at concentrations paralleling their biological potencies; and showed sensitivity to the inhibitory effects of PAF antagonists. PAF and the analogs, moreover, desensitized PMN responses to each other but not to leukotriene B4 and actually increased (or primed) PMN responses to N-formyl-MET-LEU-PHE. Finally, 5-hydroxyeicosatetraenoate-enhanced PMN responses to PAF and the analogs without enhancing the actions of other stimuli. It stereospecifically raised each analog's potency by as much as 100-fold and converted a fifth natural analog, 1-alk-1'-enyl-2-acetyl-sn-glycero-3-phosphoethanolamine from inactive to a weak stimulator of PMN. PAF and its analogs thus represent a structurally diverse family of cell-derived phospholipids which can activate, prime, and desensitize neutrophils by using a common, apparently PAF receptor-dependent mechanism.
Collapse
Affiliation(s)
- J T O'Flaherty
- Department of Medicine, Wake Forest University, Bowman Gray School of Medicine, Winston-Salem, NC 27106
| | | | | | | | | |
Collapse
|
12
|
Evangelou AM. Platelet-activating factor (PAF): implications for coronary heart and vascular diseases. Prostaglandins Leukot Essent Fatty Acids 1994; 50:1-28. [PMID: 8146205 DOI: 10.1016/0952-3278(94)90101-5] [Citation(s) in RCA: 80] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Affiliation(s)
- A M Evangelou
- Department of Exp. Physiology, Faculty of Medicine, University of Ioannina, Greece
| |
Collapse
|
13
|
Sugatani J, Miwa M, Komiyama Y, Murakami T. Quantitative analysis of platelet-activating factor in human plasma. Application to patients with liver cirrhosis and disseminated intravascular coagulation. J Immunol Methods 1993; 166:251-61. [PMID: 8288878 DOI: 10.1016/0022-1759(93)90366-f] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
A simple and reliable analytical procedure was developed for determination of platelet-activating factor (PAF) in human plasma using radioimmunoassay (RIA). The assay system consisted of lipid extraction with 2-propanol, lipid separation by Amprep octadecyl minicolumn chromatography and thin-layer chromatography and RIA (charcoal method), and was suitable for quantitation of 30-1000 pg of PAF. The sensitivity of RIA for PAF was notably higher than that for sn-2-short-chain PAF-like phosphatidylcholines. This assay system was then applied for measurement of PAF in human plasma. The normal level of plasma PAF was 54 +/- 40 pg/ml (n = 35), whereas plasma PAF levels in patients with liver cirrhosis (LC) and disseminated intravascular coagulation (DIC) were significantly elevated to 238 +/- 314 pg/ml (n = 14) and 591 +/- 328 pg/ml (n = 14), respectively. The values obtained using this assay system were comparable to those obtained by gas chromatography/mass spectrometry analysis and bioassay. These results indicate that our new assay system is useful for determining changes in the level of plasma PAF associated with diseases such as LC and DIC.
Collapse
Affiliation(s)
- J Sugatani
- Department of Medical Chemistry, Kansai Medical University, Osaka, Japan
| | | | | | | |
Collapse
|
14
|
Tsoukatos D, Demopoulos CA, Tselepis AD, Moschidis MC, Donos A, Evangelou A, Benveniste J. Inhibition by cardiolipins of platelet-activating factor-induced rabbit platelet activation. Lipids 1993; 28:1119-24. [PMID: 8121255 DOI: 10.1007/bf02537080] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Evidence is presented that cardiolipin, a naturally occurring phospholipid, inhibits the aggregatory effect of platelet-activating factor (paf) on rabbit platelets in vitro. Bovine heart cardiolipin was shown to inhibit the aggregation of washed rabbit platelets induced by 1 x 10(-10) M and 2 x 10(-10) M paf with IC50 values (doses for half-maximal inhibition) of 8.4 +/- 0.8 x 10(-7) M and 2.6 +/- 0.6 x 10(-6) M, respectively. Phosphonocardiolipin was also able to inhibit platelet aggregation induced by 1 x 10(-10) M paf with an IC50 value of 3 +/- 1 x 10(-7) M. Both compounds, in concentrations up to 1 x 10(-5) M, were unable to aggregate washed rabbit platelets and failed to inhibit the aggregation induced by 0.9 and 1.8 microM adenosine diphosphate or 0.2-1.0 microM arachidonic acid. By contrast, the acetylated derivative of cardiolipin exerted an aggregatory effect on aspirin-treated rabbit platelets in the presence of creatine phosphate/creatine phosphokinase. This aggregation was inhibited by the specific paf antagonists BN 52021 and WEB 2086. Also, platelets treated with acetyl-cardiolipin were insensitive to the aggregatory effect of paf. Phosphatidic acid, phosphatidylglycerol, bis(dipalmitoylglycero)phosphate and their phosphono analogues were totally inactive. Similar data were obtained when platelet-rich plasma was used instead of washed rabbit platelets. Our results support the hypothesis that the effect of cardiolipin is mediated through specific paf receptors that act on the rabbit platelet membrane.
Collapse
Affiliation(s)
- D Tsoukatos
- Department of Chemistry, School of Science, University of Ioannina, Greece
| | | | | | | | | | | | | |
Collapse
|
15
|
Tanaka T, Minamino H, Unezaki S, Tsukatani H, Tokumura A. Formation of platelet-activating factor-like phospholipids by Fe2+/ascorbate/EDTA-induced lipid peroxidation. BIOCHIMICA ET BIOPHYSICA ACTA 1993; 1166:264-74. [PMID: 8443246 DOI: 10.1016/0005-2760(93)90107-k] [Citation(s) in RCA: 51] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
We have identified novel phospholipids together with platelet-activating factor and its 1-acyl analogues in purified fractions from a bovine brain lipid extract. These novel compounds were phospholipids with an sn-2-short-chain monocarboxylyl, dicarboxylyl or omega-hydroxymonocarboxylyl group. The profiles of these three types of phospholipids suggest that they were formed by lipid peroxidation. To examine this possibility, we peroxidized synthetic phosphatidylcholines (PC) with an sn-2-polyunsaturated fatty acyl group and PC from bovine brain, with Fe2+/ascorbate/EDTA, and analyzed the secondary degradation products retaining a glycerol backbone by fast atom bombardment-mass spectrometry and GC-MS. Results showed the formation of four kinds of PC with a short-chain monocarboxylate, dicarboxylate, dicarboxylate semialdehyde or omega-hydroxymonocarboxylate moiety. The chain lengths of these PC were related to the position of the double bond vicinal to the esterified carbonyl group in the sn-2-long-chain acyl moiety of the parent PC. The molecular heterogeneity of secondary products formed by the oxidative degradation of bovine brain PC resembled those of the unique phospholipids that we previously detected in the fractions with platelet-activating factor-like activity purified from a bovine brain lipid extract, although the former lacked the species with an acetyl group. These results suggest that all the novel phospholipids with a short-chain acyl group in the brain lipid extract except that with an acetyl group were produced by lipid peroxidation.
Collapse
Affiliation(s)
- T Tanaka
- Faculty of Pharmaceutical Sciences, University of Tokushima, Japan
| | | | | | | | | |
Collapse
|
16
|
Satoh K, Imaizumi T, Yoshida H, Hiramoto M, Takamatsu S. Increased levels of blood platelet-activating factor (PAF) and PAF-like lipids in patients with ischemic stroke. Acta Neurol Scand 1992; 85:122-7. [PMID: 1574985 DOI: 10.1111/j.1600-0404.1992.tb04010.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Levels of platelet-activating factor (PAF) in blood from patients with ischemic stroke were determined by radioimmunoassay (RIA). Using 2 ml of blood as a starting material, PAF was detected in 11 out of 17 stroke patients and 3 of 25 age-matched healthy controls. This implies that blood level of PAF is higher in stroke patients than in controls. Plasma levels of PAF-like lipid(s) (PAF-LL) were also estimated in the same subjects by a bioassay based on aggregation of human polymorphonuclear neutrophils. PAF-LL was detected in plasma samples of all subjects and the average values in patients and controls were 294 +/- 211 pg/ml and 140 +/- 122 pg/ml, respectively. There was a statistically significant difference between these two values (p less than 0.01). Separation of plasma lipids by HPLC gave a single peak in bioassay, which had the same elution volume as authentic PAF. When each fraction was subjected to RIA, the fractions corresponded to phosphatidylcholine (PC) or lysoPC also showed the immunoreactivity, however, the purification procedure using an octadecylsilica gel cartridge eliminated such cross-reacting compounds. We conclude that blood PAF is higher in patients with ischemic stroke than in healthy subjects. Besides, there may be bioactive phospholipid molecules other than PAF, which level in plasma is also higher in stroke patients.
Collapse
Affiliation(s)
- K Satoh
- Department of Pathologic Physiology, Hirosaki University School of Medicine, Japan
| | | | | | | | | |
Collapse
|
17
|
|
18
|
Tokumura A, Yotsumoto T, Hoshikawa T, Tanaka T, Tsukatani H. Quantitative analysis of platelet-activating factor in rat brain. Life Sci 1992; 51:303-8. [PMID: 1625522 DOI: 10.1016/0024-3205(92)90089-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Age-related decrease of the platelet-activating factor (PAF) content in rat brain was shown by a convenient method consisting of solid extraction of lipids with a Sep-Pak C-18 cartridge, lipid separation by HPLC and bioassay on rabbit platelets. This method was sufficiently sensitive to allow measurement of PAF in a single brain, and the recovery of PAF was quite high throughout the procedure.
Collapse
Affiliation(s)
- A Tokumura
- Faculty of Pharmaceutical Sciences, University of Tokushima, Japan
| | | | | | | | | |
Collapse
|
19
|
Abstract
Approximately 75% of the PAF present in saliva is recovered on extraction of whole saliva (0.8 vol) with chloroform/methanol/water (2:2:1, v/v/v). PAF levels, determined by our recently developed radioimmunoassay, in saliva extracts ranged from 0.5-21 ng/mL with 59% between 2-6 ng/mL. These figures, for apparently healthy subjects, are higher than previously reported levels obtained by platelet assays. The validity of our radioimmunoassay results was checked by isolating and quantitating the PAF fraction from whole saliva. In addition, when we examined our saliva samples by platelet aggregation, low levels of PAF, comparable with the values found in the literature, were detected. Investigations revealed the presence of a substance(s) which inhibited PAF-induced platelet aggregation but which did not affect the radioimmunoassay.
Collapse
Affiliation(s)
- S J Cooney
- Kolling Institute of Medical Research, Royal North Shore Hospital, St. Leonards, N.S.W., Australia
| | | | | |
Collapse
|
20
|
Heuer HO, Darius H, Lohmann HF, Meyer J, Schierenberg M, Treese N. Platelet-activating factor type activity in plasma from patients with septicemia and other diseases. Lipids 1991; 26:1381-5. [PMID: 1819737 DOI: 10.1007/bf02536571] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The purpose of the present study was to determine whether increased levels of platelet-activating factor (PAF) type activity can be detected in plasma from patients with septicemia and other diseases. A level of PAF below 0.5 ng/mL of plasma was considered normal. We found that plasma from a patient with adverse anaphylactoidic reaction to intravenous analgetics contained 2.1 ng PAF/mL. In seven patients with septicemia, including urosepsis, endocarditis and peritonitis, and with positive blood culture, increased plasma PAF levels (1-20 ng PAF/mL) were observed. Other patients with clinical indications of septicemia had negative blood cultures and/or increased levels of C-reactive protein (CRP). Yet, in the plasma from these patients, no increased PAF levels were detected under the assay conditions used. Two patients with allergic asthma, requiring treatment with steroids, had no measurable plasma PAF. In the plasma from a patient with idiopathic thrombocytopenic purpura (ITP) only an "endogenous" inhibitor of PAF induced platelet aggregation was initially observed. In spite of this, the patient responded to treatment with the PAF antagonist WEB 2086 with a dramatic increase in platelet count (Lohmann et al., Lancet ii, 1147, 1988). Thereafter, also increased PAF levels (3.3 ng PAF/mL) were detected in plasma, although some "endogenous" inhibitor of PAF was still present. In conclusion, increased PAF levels in plasma from patients support a role of PAF in certain human disease states, such as in anaphylactoid reaction, sepsis and septic shock. The type, relevance and specificity of endogenous inhibitors of PAF deserve further study.
Collapse
Affiliation(s)
- H O Heuer
- Department of Pharmacology, Boehringer Ingelheim, Germany
| | | | | | | | | | | |
Collapse
|
21
|
Abstract
A specific radioimmunoassay for platelet-activating factor (PAF) sensitive in the range 10-1000 pg (0.02-2 pmoles) has been developed. Detailed quantitative hapten inhibition studies showed specificity for the acetyl group at C-2 of PAF, a requirement for the ether linkage at C-1 and some tolerance for substituents on the choline nitrogen. No significant cross-reactivity was found with phosphatidylcholine and lysophosphatidylcholine or with lysoPAF.
Collapse
Affiliation(s)
- B A Baldo
- Kolling Institute of Medical Research, Royal North Shore Hospital of Sydney, St. Leonards, N.S.W., Australia
| | | | | |
Collapse
|
22
|
Abstract
Quantitation of platelet-activating factor (PAF) in human saliva samples by radioimmunoassay indicated there was, at times, sufficient PAF present to aggregate platelets. However, in certain samples, we observed little or no aggregation, and furthermore, these samples were found to inhibit aggregation induced by PAF (200 pg). Chromatographic fractionation of pooled saliva increased the PAF activity 4-fold, and the observed inhibitory activity was found to co-migrate with the fatty acids. The inhibitory fraction was found to be active against platelet aggregation induced by arachidonic acid (3.4 nmole) as well as PAF (25 pg), but not thrombin (20 mU). These results indicate the existence of a PAF inhibitor in saliva, which may explain why potentially toxic levels of PAF can occur in the saliva of normal, healthy individuals. These findings also highlight an important advantage of the radioimmunoassay over platelet aggregation for the quantitation of PAF in, at least, some biological fluids.
Collapse
Affiliation(s)
- M A Smal
- Kolling Institute of Medical Research, Royal North Shore Hospital, St. Leonards, N.S.W., Australia
| | | |
Collapse
|
23
|
Ikeda I, Oda M, Sakakura M, Yasunaga K. Presence of platelet-activating factor in pyuria in humans. Lipids 1991; 26:1333-5. [PMID: 1819727 DOI: 10.1007/bf02536560] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The relationship between the occurrence of platelet-activating factor (PAF) and neutrophils in urine from patients with urinary tract infection was examined. PAF was detected in human pyuria, when leukocyte levels reached at least 300 cells/microL (n = 45), but not in normal urine (n = 12). The amount of PAF found in pyuria, measured by platelet aggregation assay, was 0.01 to 13.3 pmol/mL. A close correlation was seen between the amount of PAF present and the number of urinary leukocytes (p less than 0.01, r = 0.70). The leukocytes in pyuria consisted almost entirely of neutrophils (96 +/- 4%, mean +/- S.D.). Our findings suggest that the occurrence of PAF is associated with the accumulation of neutrophils in urine.
Collapse
Affiliation(s)
- I Ikeda
- Department of Internal Medicine, Saiseikai Izuo Hospital, Osaka, Japan
| | | | | | | |
Collapse
|
24
|
Adamson LM, Podsiadly B, Smart YC, Stanger JD, Roberts TK. Studies on murine embryo-derived platelet-activating factor (EPAF). Mol Reprod Dev 1991; 30:207-13. [PMID: 1793598 DOI: 10.1002/mrd.1080300307] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Studies were carried out using the splenectomized mouse bioassay (SMB) to investigate the nature of embryo-derived platelet-activating factor (EPAF) and its relationship to synthetic platelet activating factor (PAF). While both C16-PAF and embryo conditioned media (ECM) induced a significant platelet decline in the SMB at 15 min postinjection, C18-PAF induced a similar effect at 30 min postinjection. The degree of EPAF activity in ECM was not altered with increasing embryo number from 2 to 40/ml of media. In contrast, PAF (C16/C18 mixture) induced a linear increase in activity with increasing concentration, leading to lethal effects at high concentrations. While EPAF activity was not significantly altered when ECM was diluted 1/1,000, PAF activity was abolished at 1/10 dilution. EPAF in ECM was not inactivated by mouse plasma; however, lipid extracted ECM, like PAF, underwent rapid inactivation in the presence of plasma. Aggregometer studies using horse platelets showed that ECM and lipid-extracted ECM were unable to induce platelet aggregation, while thin-layer chromatography (TLC) purified ECM (Rf 0.23) successfully aggregated horse platelets in vitro. Results suggested that EPAF and PAF are not homologous. EPAF might consist of PAF bound to a regulatory carrier molecule and appears to be associated with EPAF-inhibitor substance(s) in ECM.
Collapse
Affiliation(s)
- L M Adamson
- Department of Biological Sciences and Discipline of Surgical Science, University of Newcastle, New South Wales, Australia
| | | | | | | | | |
Collapse
|
25
|
Sugatani J, Fujimura K, Mizuno T, Sameshima Y, Saito K. The role of platelet activating factor (PAF) in the pathogenesis of gastric ulcers. Prostaglandins Leukot Essent Fatty Acids 1991; 44:135-47. [PMID: 1808623 DOI: 10.1016/0952-3278(91)90048-a] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- J Sugatani
- Department of Medical Chemistry, Kansai Medical University, Osaka, Japan
| | | | | | | | | |
Collapse
|
26
|
Nakayama R, Yasuda K, Okumura T, Saito K. Effect of 17 beta-estradiol on PAF and prostaglandin levels in oophorectomized rat uterus. BIOCHIMICA ET BIOPHYSICA ACTA 1991; 1085:235-40. [PMID: 1892893 DOI: 10.1016/0005-2760(91)90099-4] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The effects of 17 beta-estradiol on the levels of platelet-activating factor (PAF) and prostaglandins and their precursor phospholipid in the uterus of oophorectomized rats were studied. Oophorectomy results in the decrease in the uterine PAF level to one-third of that in natural estrus. This level was recovered by subcutaneous administration of 17 beta-estradiol. The level of uterine phospholipids, which are rich in arachidonic acid, was significantly decreased by estradiol treatment. More arachidonate-PC was depleted than arachidonate-PE. The molecular structure was confirmed by gas chromatography-mass spectrometry. The amount of PGF2 alpha in the oophorectomized uterine tissue was 10-times that of PAF, but like the latter, increased 3-4 times on estradiol treatment. The chemical structures of PAF and PGF2 alpha formed on estradiol treatment were confirmed by mass spectrometry. The present data strongly suggest a correlation between the formations of PAF and PGF2 alpha, and indicate that estradiol may regulate the physiological formations of PAF and PGs in non-pregnant rat uterus.
Collapse
Affiliation(s)
- R Nakayama
- Department of Medical Chemistry, Kansai Medical School Moriguchi, Osaka, Japan
| | | | | | | |
Collapse
|
27
|
Cooney SJ, Smal MA, Baldo BA. Stability of platelet activating factor (PAF) in human saliva. Quantitation by radioimmunoassay. Clin Chim Acta 1991; 200:161-73. [PMID: 1777966 DOI: 10.1016/0009-8981(91)90087-s] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Platelet activating factor (PAF) is thought to mediate many inflammatory processes and its involvement in health and disease may be clarified by examining PAF levels in human secretions. The known presence of PAF, the ease of obtaining samples and the relative stability of PAF in saliva, makes this fluid a preferred source for examination of PAF in health and disease. The activity of PAF-acetylhydrolase (the PAF degrading enzyme) in saliva was 1,000-fold lower than that found in human plasma. Extraction of saliva with chloroform/methanol/water resulted in 70-90% recovery of PAF. Using the radioimmunoassay (RIA), PAF levels in the range 0.5-21 ng/ml were found in normal human salivas. These values were significantly higher than those reported from bioassay studies based on washed platelets. The validity of the RIA was checked by isolating and quantitating the PAF fraction from whole saliva extract, and by treatment of the extracts with the enzyme phospholipase A2. Direct comparison of salivary PAF levels, determined by both platelet aggregation (PA) and RIA confirmed our original finding that values obtained were lower using the bioassay method. Furthermore, these bioassay values compared favourably with those in the literature. Investigations revealed the presence of a substance(s) in saliva which inhibited PAF-induced platelet aggregation but which did not affect the radioimmunoassay.
Collapse
Affiliation(s)
- S J Cooney
- Kolling Institute of Medical Research, Royal North Shore Hospital, St. Leonards, N.S.W., Australia
| | | | | |
Collapse
|
28
|
Kudolo GB, Kasamo M, Harper MJ. Autoradiographic localization of platelet-activating factor (PAF) binding sites in the rabbit endometrium during the peri-implantation period. Cell Tissue Res 1991; 265:231-41. [PMID: 1657393 DOI: 10.1007/bf00398071] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
This communication describes the use of in-vivo and in-vitro autoradiography to map specific platelet-activating factor (PAF) receptors in the rabbit uterus. Specific [3H]PAF uptake was predominantly localized on epithelial, but not on stromal or myometrial cells. Very few silver grains were associated with the luminal epithelial cells in the uterus of the estrous rabbit, primarily because of the non-differentiated state of the epithelium. In the differentiated pregnant uterus, significantly more [3H]PAF was bound to the glandular epithelial cells, with the stromal cells binding consistently significantly less. The highest density of silver grains was observed at the implantation sites on day 7 of pregnancy. There was no apparent difference in [3H]PAF C18:0 uptake between the epithelial cells at the inter-implantation zone on day 7 and on day 6. Bound [3H]PAF was displaceable by lyso-PAF, U66985, CV3988, but not U66982, L652,731, SRI 63,441 or the inactive PAF isomer, oleoyl PAF. Bovine serum albumin (BSA) significantly inhibited tissue uptake of [3H]PAF C18:0. Intraluminally administered [3H]PAF C18:0 and intravenously injected [3H]methylcarbamyl-PAF, a non-metabolizable PAF analog, penetrated the implanted blastocyst and bound to the embryoblast. This event was reproducible in vitro with pre-implantation blastocysts from day-6 pregnant rabbits, which suggests that uterine-derived PAF may translocate into the blastocyst after attachment.
Collapse
Affiliation(s)
- G B Kudolo
- Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio 78284-7836
| | | | | |
Collapse
|
29
|
Holleran WM. Lipid modulators of epidermal proliferation and differentiation. ADVANCES IN LIPID RESEARCH 1991; 24:119-39. [PMID: 1763711 DOI: 10.1016/b978-0-12-024924-4.50009-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The importance of lipids within the skin as components of the permeability barrier has been appreciated for quite some time. However, the more recent work reviewed here suggests numerous alternative bioactive functions for lipid molecules within the skin and other tissues. The precise roles of lipids in epidermal proliferation and differentiation have only begun to be studied and are far from being defined.
Collapse
Affiliation(s)
- W M Holleran
- Department of Dermatology, University of California School of Medicine, San Francisco 94143
| |
Collapse
|
30
|
Abstract
PAF, a potent phospholipid mediator of inflammation, is present in normal human, mixed saliva. However, the anatomic origin of PAF is not known. In this study, PAF levels in mixed saliva of edentulous subjects were estimated in comparison to that of dentate individuals. PAF activity was assessed in bioassay and expressed relative to the activity of known amounts of authentic PAF, 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine (AGEPC). PAF was not detected in the saliva of 60% of the edentulous subjects; moreover, when present, the PAF levels were significantly less (635 +/- 82 AGEPC fmole equivalents/ml saliva, mean +/- SEM, n = 6) than in dentate subjects (5568 +/- 1135 AGEPC fmole equivalents/ml saliva, n = 27). Of relevance, the numbers of polymorphonuclear leukocytes in the mixed saliva samples of edentulous subjects were markedly reduced when compared to those of normal subjects. These findings suggest that salivary PAF most likely originates from the crevicular space, and derives from inflammatory cells within the gingival and/or periodontal tissues.
Collapse
Affiliation(s)
- L M McManus
- Department of Pathology, University of Texas Health Science Center, San Antonio
| | | | | |
Collapse
|
31
|
Snyder F. Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. THE AMERICAN JOURNAL OF PHYSIOLOGY 1990; 259:C697-708. [PMID: 2240190 DOI: 10.1152/ajpcell.1990.259.5.c697] [Citation(s) in RCA: 284] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Platelet-activating factor (PAF or 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is the most potent lipid mediator yet discovered. It is known to stimulate a wide span of biological responses ranging from aggregation and degranulation of platelets and neutrophils to a variety of cellular effects involving the stimulation of chemotaxis; chemokinesis; superoxide formation; protein phosphorylation; activation of protein kinase C, arachidonic acid, and phosphoinositide metabolites; glycogenolysis; and tumor necrosis factor production. Obviously, with such a diversity of biological activities, it is not surprising that PAF has been considered to be a key component in numerous diseases related to hypersensitivity and inflammatory responses. Evidence has also been presented for the role of PAF in physiological processes, particularly those involving reproduction and fetal development. Furthermore, because of its potent hypotensive action, PAF has been implicated as a contributing factor in blood pressure regulation. PAF is produced by two independent enzymatic pathways. The remodeling route involves the structural modification of a membrane lipid (1-alkyl-2-acyl-sn-glycero-3-phosphocholine) by replacement of the acyl moiety with an acetate group. An alternate route is the de novo synthesis of PAF from an O-alkyl analogue of a lysophosphatidic acid that requires a reaction sequence of acetylation, dephosphorylation, and phosphocholine addition steps. Hypersensitivity and other pathophysiological reactions are thought to be caused by activation of the remodeling pathway, whereas the de novo route is believed to be the source of endogenous levels of PAF required for physiological functions. Inactivation of PAF occurs when the acetate group is hydrolyzed by an acetylhydrolase that is present in both extra- and intracellular compartments, although the catalytic activity of the two forms of acetylhydrolase are identical, some of their properties differ. The control of PAF metabolism is very complex, but acetylhydrolase, Ca2+, phosphorylation/dephosphorylation of enzymes, and fatty acids (especially polyunsaturates) appear to be important regulatory factors. Specific PAF receptors have clearly been demonstrated on several different types of cells, and although the mechanism of PAF actions is poorly understood, it appears that the PAF/receptor-induced responses are closely associated with the signal transduction process; both G proteins and adenyl cyclase appear to be involved. Because significant quantities of PAF are often retained within certain cells, the possibility of PAF serving as an intracellular mediator has also been proposed.
Collapse
Affiliation(s)
- F Snyder
- Medical Sciences Division, Oak Ridge Associated Universities, Tennessee 37831-0117
| |
Collapse
|
32
|
|
33
|
Sugatani J, Lee DY, Hughes KT, Saito K. Development of a novel scintillation proximity radioimmunoassay for platelet-activating factor measurement: comparison with bioassay and GC/MS techniques. Life Sci 1990; 46:1443-50. [PMID: 2111868 DOI: 10.1016/0024-3205(90)90460-9] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
A novel, facile and sensitive scintillation proximity radioimmunoassay (SPRIA) for quantitation of PAF has been developed. No separation of antibody bound [3H]PAF from free [3H]PAF is required as the assay employs protein A - coated fluomicrospheres (beads containing scintillant). The assay system was suitable for the quantitation of 0.03 to 2 pmol of 1-hexadecyl-2-acetyl-sn-glycero-3- phosphocholine. The cross-reactivity was high with 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine but was very low with PAF analogs such as 1-alkyl- and 1-acyl-2-lyso-sn-glycero-3-phosphocholine, 1-acyl-2-acetyl-sn-glycero-3-phosphocholine, and 1-alk-1'-enyl-2-acetyl-sn-glycero-3-phosphocholine. The specificity of SPRIA was higher than that of bioassay (platelet degranulation assay). PAF receptor antagonists (L-652,731, WEB2086, and FR900452) at up to 10 nmol per tube had no affect on the SPRIA. These observations indicate that the specificity of the PAF antibody is quite different from that of the platelet receptor. The values obtained using SPRIA for the measurement of PAF produced in polymorphonuclear leukocytes with stimuli are comparable to those obtained by SIM/GC/MS analysis.
Collapse
Affiliation(s)
- J Sugatani
- Department of Medical Chemistry, Kansai Medical School, Osaka, Japan
| | | | | | | |
Collapse
|
34
|
Snyder F, Lee TC, Blank ML. Platelet-activating factor and related ether lipid mediators. Biological activities, metabolism, and regulation. Ann N Y Acad Sci 1989; 568:35-43. [PMID: 2698076 DOI: 10.1111/j.1749-6632.1989.tb12488.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- F Snyder
- Medical Sciences Division, Oak Ridge Associated Universities, Tennessee 37831-0117
| | | | | |
Collapse
|
35
|
Nakayama R, Yasuda K, Satouchi K, Saito K. 1-O-hexadec-1'-enyl-2-acetyl-sn-glycero-3-phosphocholine and its biological activity. Biochem Biophys Res Commun 1988; 151:1256-61. [PMID: 3355555 DOI: 10.1016/s0006-291x(88)80501-1] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
1-O-Alk-1'-enyl analog of platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine, alkylacetyl-GPC) was prepared semi-synthetically from choline plasmalogens of beef heart muscle. The main compound was identified mass spectrometrically as 1-hexadec-1'-enyl-2-acetyl-sn-glycero-3-phosphocholine (16:O alk-1'-enylacetyl-GPC, 16:O vinyl form of PAF) and its platelet aggregation activity was about one-fifth of that of the corresponding 16:O alkylacetyl-GPC. The irreversible platelet aggregation activity induced by 5X10(-10) M 16:O alk-1'-enylacetyl-GPC was completely inhibited by 5X10(-7) M CV-3988 and 1X10(-7) M L-652, 731, specific PAF antagonists, and more than 99% of the activity was also lost by acid treatment. The hydrogenated product, alkylacetyl analog, showed quite same activity as that of authentic 16:O alkylacetyl-GPC. The platelets desensitized with 16:O alkylacetyl-GPC and with 16:O alk-1'-enylacetyl-GPC were not aggregated with 5X10(-10) M 16:O alk-1'-enylacetyl-GPC, suggesting that alk-1'-enylacetyl-GPC occupied the same receptor site of alkylacetyl-GPC.
Collapse
Affiliation(s)
- R Nakayama
- Department of Medical Chemistry, Kansai Medical School, Osaka, Japan
| | | | | | | |
Collapse
|